Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Drug-naïve Drug-naïve Drug naïvety is the physiological state of non-habituation or non-tolerance to either a specific drug or broader set of drugs related by pharmacological criteria. The term applies to the administration of psychotropics in contexts ranging from the professional medical treatment of patients to the non-medical abuse of any drug, as well as the veterinarian. In addition to not being habituated, a drug-naïve person may have never received a particular drug. The same dose could be lethal for a drug-naive person while having little effect on a heavily habituated person. In a medical context drug-naïvete is important considering medication dosage